| Trial ID: | L6796 |
| Source ID: | NCT00745433
|
| Associated Drug: |
Repaglinide
|
| Title: |
Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide
|
| Acronym: |
REPAMET 2
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: metformin
|
| Outcome Measures: |
Primary: HbA1c, After 12-20 weeks. | Secondary: PPG, After 12-20 weeks.|Number of hypoglycemic events, After 12-20 weeks.|Variability in FPG (Fasting Plasma Glucose), After 12-20 weeks.
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
906
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-01
|
| Completion Date: |
2009-03
|
| Results First Posted: |
|
| Last Update Posted: |
2023-11-02
|
| Locations: |
Brussels, 1070, Belgium
|
| URL: |
https://clinicaltrials.gov/show/NCT00745433
|
